BRPI0508404A - derivado de (indol-3-il)-heterociclo, composição farmacêutica, uso de um derivado de (indol-3-il)-heterociclo, e método de tratamento da dor - Google Patents
derivado de (indol-3-il)-heterociclo, composição farmacêutica, uso de um derivado de (indol-3-il)-heterociclo, e método de tratamento da dorInfo
- Publication number
- BRPI0508404A BRPI0508404A BRPI0508404-0A BRPI0508404A BRPI0508404A BR PI0508404 A BRPI0508404 A BR PI0508404A BR PI0508404 A BRPI0508404 A BR PI0508404A BR PI0508404 A BRPI0508404 A BR PI0508404A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- alkyloxy
- indol
- pain
- halogen
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 6
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000001041 indolyl group Chemical group 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DERIVADO DE (INDOL-3-IL)-HETEROCICLO, COMPOSIçãO FARMACêUTICA, USO DE UM DERIVADO DE (INDOL-3-IL)-HETEROCICLO, E, MéTODO DE TRATAMENTO DA DOR A invenção diz respeito a derivados de (indol-3-il)-heterociclo tendo a Fórmula Geral (I) em que A representa um anel heterocíclico aromático de 5 membros, em que X~ 1~, X~ 2~ e X~ 3~ são independentemente selecionados de N, O, S e CR; R é H ou alquila C~ 1-4~; ou R, quando presente em X~ 2~ ou X~ 3~, pode formar, junto com R~ 3~, um anel de 5 a 8 membros; R~ 1 é um anel carbocíclico saturado de 5 a 8 membros, opcionalmente contendo um heteroátomo selecionado de O e S; R~ 2~ é H, CH~ 3~ ou CH~ 2~-CH~ 3~; ou R~ 2~ é unido a R~ 7~ para formar um anel de 6 membros, opcionalmente contendo um heteroátomo selecionado de O e S, e em que o heteroátomo é ligado à posição 7 do anel indol; R~ 3~ e R~ 4~ são independentemente H, alquila C~ 1-6~ ou cicloalquila C~ 3-7~, os grupos alquila sendo opcionalmente substituídos por OH, alquilóxi C~ 1-4~, alquiltio C~ 1-4~, alquila C~ 1-4~-sulfonila, CN ou halogênio; ou R~ 3~, junto com R~ 4~ e o N a que eles se acham ligados, formam um anel de 4 a 8 membros opcionalmente contendo um outro heteroátomo selecionado de O e S, e o qual é opcionalmente substituído por OH, alquila C~ 1-4~, alquilóxi C~ 1-4~, alquilóxi C~ 1-4~-alquila C~ 1-4~ ou halogênio; ou R~ 3~, junto com R~ 5~, forma um anel de 4 a 8 membros opcionalmente contendo um outro heteroátomo selecionado de O e S, e o qual é opcionalmente substituído por OH, alquila C~ 1-4~, alquilóxi C~ 1-4~, alquilóxi C~ 1-4~-alquila C~ 1-4 ou halogênio; ou R~ 3~, junto com R, quando presente em X~ 2~ ou X~ 3~, forma um anel de 5 a 8 membros; R~ 5~ é H ou alquila C~ 1-4~; ou R~ 5~, junto com R~ 3~, forma um anel de 4 a 8 membros opcionalmente contendo um outro heteroátomo selecionado de O e S, e o qual é opcionalmente substituído por OH, alquila C~ 1-4~, alquilóxi C~ 1-4~, aquilóxi C~ 1-4~-aquila C~ 1-4~ ou halogênio; R~ 5~' é H ou alquila C~ 1-4~; R~ 6~ representa de 1 a 3 substituintes independentemente selecionados de H, alquila C~ 1-4~, alquilóxi C~ 1-4~, CN e halogênio; R~ 7~ é H, alquila C~ 1-4~, alquilóxi C~ 1-4~, CN ou halogênio; R~ 7~, unido com R~ 2~ para formar um anel de 6 membros, opcionalmente contendo um outro heteroátomo selecionado de O e S, e cujo heteroátomo é ligado à posição 7 do anel indol; ou um seu sal farmaceuticamente aceitável, como agonistas do receptor CB1 canabinóide, o qual pode ser usado tratamento da dor, tal como, por exemplo, a dar perioperatória, a dor crónica, a dor neuropática, a dor do câncer e a dor e a espasticidade associadas com a esclerose múltipla.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55056304P | 2004-03-05 | 2004-03-05 | |
| EP04100902 | 2004-03-05 | ||
| EP04103901 | 2004-08-12 | ||
| PCT/EP2005/050833 WO2005089754A1 (en) | 2004-03-05 | 2005-02-28 | (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0508404A true BRPI0508404A (pt) | 2007-07-17 |
Family
ID=36608981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0508404-0A BRPI0508404A (pt) | 2004-03-05 | 2005-02-28 | derivado de (indol-3-il)-heterociclo, composição farmacêutica, uso de um derivado de (indol-3-il)-heterociclo, e método de tratamento da dor |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7700634B2 (pt) |
| EP (1) | EP1725232B1 (pt) |
| JP (1) | JP5011097B2 (pt) |
| AR (1) | AR048745A1 (pt) |
| AT (1) | ATE384525T1 (pt) |
| AU (1) | AU2005224041B2 (pt) |
| BR (1) | BRPI0508404A (pt) |
| CA (1) | CA2557054C (pt) |
| DE (1) | DE602005004515T2 (pt) |
| DK (1) | DK1725232T3 (pt) |
| ES (1) | ES2300995T3 (pt) |
| MY (1) | MY139070A (pt) |
| NZ (1) | NZ549386A (pt) |
| PE (1) | PE20060074A1 (pt) |
| PL (1) | PL1725232T3 (pt) |
| PT (1) | PT1725232E (pt) |
| RS (1) | RS20060502A (pt) |
| SI (1) | SI1725232T1 (pt) |
| TW (1) | TWI330635B (pt) |
| WO (1) | WO2005089754A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI330635B (en) | 2004-03-05 | 2010-09-21 | Organon Nv | (indol-3-yl)-heterocycle derivatives |
| TW200745096A (en) * | 2005-08-23 | 2007-12-16 | Organon Nv | Indole derivatives |
| US7763732B2 (en) | 2005-08-24 | 2010-07-27 | N.V. Organon | Indole derivatives |
| GB0614062D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
| GB0614066D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
| TW200848417A (en) * | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
| EP3452036A4 (en) | 2016-05-04 | 2019-11-06 | Inmed Pharmaceuticals Inc. | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND ASSOCIATED BINDING WEB DISEASES |
| US12357604B2 (en) | 2017-09-22 | 2025-07-15 | Inmed Pharmaceuticals Inc. | Topical formulations of cannabinoids and use thereof in the treatment of pain |
| WO2022128050A1 (en) | 2020-12-14 | 2022-06-23 | Symrise Ag | Medicament for fighting inflammation and pain |
| WO2025090587A1 (en) | 2023-10-23 | 2025-05-01 | Inmed Pharmaceuticals Inc. | Cannabinoids compounds and their use in the treatment of neuronal disorders |
| WO2025090133A1 (en) | 2023-10-23 | 2025-05-01 | Inmed Pharmaceuticals Inc. | Compositions and methods for use of cannabinol compounds in neuroprotection |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ227841A (en) * | 1988-02-12 | 1991-08-27 | Merck Sharp & Dohme | Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions |
| US4939138A (en) | 1988-12-29 | 1990-07-03 | Sterling Drug Inc. | 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines |
| CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| AUPR118000A0 (en) | 2000-11-02 | 2000-11-23 | Amrad Operations Pty. Limited | Therapeutic molecules and methods |
| ATE478670T1 (de) | 2001-01-29 | 2010-09-15 | Univ Connecticut | Rezeptor-selektive cannabimimetische aminoalkylindole |
| TW200402417A (en) | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
| AU2004298782B2 (en) | 2003-12-17 | 2010-06-17 | Merck Sharp & Dohme B.V. | Tricyclic 1-[(3-indol-3-yl)carbonyl] piperazine derivatives as cannabinoid CB1 receptor agonists |
| TWI330635B (en) | 2004-03-05 | 2010-09-21 | Organon Nv | (indol-3-yl)-heterocycle derivatives |
| TW200745096A (en) | 2005-08-23 | 2007-12-16 | Organon Nv | Indole derivatives |
| US7763732B2 (en) * | 2005-08-24 | 2010-07-27 | N.V. Organon | Indole derivatives |
| TW200848417A (en) | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
-
2005
- 2005-02-21 TW TW094105061A patent/TWI330635B/zh not_active IP Right Cessation
- 2005-02-28 AT AT05716823T patent/ATE384525T1/de active
- 2005-02-28 JP JP2007501270A patent/JP5011097B2/ja not_active Expired - Fee Related
- 2005-02-28 DK DK05716823T patent/DK1725232T3/da active
- 2005-02-28 DE DE602005004515T patent/DE602005004515T2/de not_active Expired - Lifetime
- 2005-02-28 PT PT05716823T patent/PT1725232E/pt unknown
- 2005-02-28 EP EP05716823A patent/EP1725232B1/en not_active Expired - Lifetime
- 2005-02-28 AU AU2005224041A patent/AU2005224041B2/en not_active Ceased
- 2005-02-28 SI SI200530186T patent/SI1725232T1/sl unknown
- 2005-02-28 WO PCT/EP2005/050833 patent/WO2005089754A1/en not_active Ceased
- 2005-02-28 ES ES05716823T patent/ES2300995T3/es not_active Expired - Lifetime
- 2005-02-28 CA CA2557054A patent/CA2557054C/en not_active Expired - Fee Related
- 2005-02-28 RS RSP-2006/0502A patent/RS20060502A/sr unknown
- 2005-02-28 PL PL05716823T patent/PL1725232T3/pl unknown
- 2005-02-28 BR BRPI0508404-0A patent/BRPI0508404A/pt not_active IP Right Cessation
- 2005-02-28 US US10/590,674 patent/US7700634B2/en not_active Expired - Fee Related
- 2005-02-28 NZ NZ549386A patent/NZ549386A/en unknown
- 2005-03-02 MY MYPI20050850A patent/MY139070A/en unknown
- 2005-03-04 AR ARP050100825A patent/AR048745A1/es not_active Application Discontinuation
- 2005-03-04 PE PE2005000245A patent/PE20060074A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007526281A (ja) | 2007-09-13 |
| TWI330635B (en) | 2010-09-21 |
| CA2557054A1 (en) | 2005-09-29 |
| ES2300995T3 (es) | 2008-06-16 |
| JP5011097B2 (ja) | 2012-08-29 |
| PT1725232E (pt) | 2008-03-04 |
| AR048745A1 (es) | 2006-05-24 |
| SI1725232T1 (sl) | 2008-06-30 |
| ATE384525T1 (de) | 2008-02-15 |
| US20070142446A1 (en) | 2007-06-21 |
| AU2005224041A1 (en) | 2005-09-29 |
| DE602005004515D1 (de) | 2008-03-13 |
| EP1725232B1 (en) | 2008-01-23 |
| NZ549386A (en) | 2009-12-24 |
| DE602005004515T2 (de) | 2009-01-29 |
| RS20060502A (sr) | 2008-11-28 |
| US7700634B2 (en) | 2010-04-20 |
| MY139070A (en) | 2009-08-28 |
| CA2557054C (en) | 2013-02-19 |
| DK1725232T3 (da) | 2008-05-26 |
| TW200602316A (en) | 2006-01-16 |
| AU2005224041B2 (en) | 2011-03-10 |
| PE20060074A1 (es) | 2006-02-18 |
| PL1725232T3 (pl) | 2008-07-31 |
| WO2005089754A1 (en) | 2005-09-29 |
| EP1725232A1 (en) | 2006-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
| NO20081970L (no) | Sulfonamidderivat med PGD2-reseptorantagonistaktivitet | |
| EA201000046A1 (ru) | Замещенные имидазогетероциклы | |
| BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
| BR0306208A (pt) | Compostos de dibenzilamina e seu uso farmacêutico | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| BRPI0413233A (pt) | novos compostos | |
| DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| BR0311494A (pt) | Novos indóis substituìdos | |
| BRPI0517314A (pt) | derivados de indol e benzimidazol | |
| BRPI0410711A (pt) | novos compostos | |
| BRPI0509761B8 (pt) | compostos de quinolinona-carboxamida como agonistas de receptor de 5-ht4, composição farmacêutica, uso dos referidos compostos e seu processo de preparação | |
| BRPI0919812A8 (pt) | Combinações de compostos antibacterianos heterocíclicos hirdrogenados com outros compostos antibacterianos e o uso dos mesmos como medicamentos | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
| CY1107677T1 (el) | Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine | |
| AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| BRPI0508404A (pt) | derivado de (indol-3-il)-heterociclo, composição farmacêutica, uso de um derivado de (indol-3-il)-heterociclo, e método de tratamento da dor | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| BR0311593A (pt) | Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc | |
| EA200702058A1 (ru) | Новые фармацевтические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |